Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
inflammation
Pharma
Apellis homes in on possible source of rare Syfovre side effect
While nothing is certain yet, Apellis may be homing in on the source of a rare but serious side effect tied to its geographic atrophy drug Syfovre.
Fraiser Kansteiner
Aug 23, 2023 9:28am
Apellis bolsters case for Syfovre amid second-quarter earnings
Jul 31, 2023 9:58am
Experts report eye inflammation cases linked to Apellis' Syfovre
Jul 17, 2023 5:30pm
AstraZeneca mounts dual campaigns to discuss asthma inflammation
Jul 7, 2023 6:10am
Arcutis will soon file roflumilast foam for new potential nod
Sep 9, 2022 11:47am
Dupixent rolled on with another phase 3 win in prurigo nodularis
Sep 9, 2022 11:30am
